Given the dependence of PCa cells on androgens for growth, proliferation, survival, and differentiation, the primary treatment for men with advanced PCa is androgen deprivation therapy (ADT), which is being increasingly supplemented with a new generation of potent androgen synthesis inhibitors (abiraterone) or androgen receptor (AR) antagonists bicalutamide, enzalutamide, and apalutamide [2, 3], hereafter cumulatively termed androgen-targeted therapies (ATTs). This evidence concerns the gene AR and posterior cortical atrophy.